Jardim, Denis L Fontes <br/><br/>
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.  [electronic resource] 

 -  Oncotarget  Apr 2014 
 - 1837-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.1828  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>DNA Mutational Analysis<br/>DNA, Neoplasm--genetics<br/>Disease-Free Survival<br/>Esophageal Neoplasms--drug therapy<br/>Esophagogastric Junction<br/>Female<br/>Gene Amplification<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins c-met--antagonists & inhibitors<br/>Stomach Neoplasms--drug therapy<br/>Survival Rate